Business
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
PASADENA, Calif., January 08, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of its concurrent public offerings of (i) $625,000,000 aggregate principal amount of 0.00% convertible senior notes due 2032 (the "notes") and (ii) 3,100,776 shares of common stock, at a public offering price of $64.50 per share (or, in lieu of shares of common stock to certain investors, pre-funded warrants, at a public offering price of $64.499 per pre-funded warrant, for up to 1,550,
About this update from Arrowhead Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1609,"height":335,"url":"https://media.zenfs.com/en/business-wire.com/5fded6741d0c430ebb60b9da688cf8e9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hlgpf0UsTcZx7QYegLyj0w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5fded6741d0c430ebb60b9da688cf8e9","width":960,"height":200},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/7wHxF4BvdlnSdSj9c1BUcw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/5fded6741d0c430ebb60b9da688cf8e9","width":1200,"height":250}},"lazy":false},{"type":"text","content":"PASADENA, Calif., January 08, 2026--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of its concurrent public offerings of (i) $625,000,000 aggregate principal amount of 0.00% convertible senior notes due 2032 (the "notes") and (ii) 3,100,776 shares of common stock, at a public offering price of $64.50 per share (or, in lieu of shares of common stock to certain investors, pre-funded warrants, at a public offering price of $64.499 per pre-funded warrant, for up to 1,550,387 shares of common stock). The offering size of the note offering was increased from the previously announced offering size of $500,000,000 aggregate principal amount of notes. The issuance and sale of the notes are scheduled to settle on January 12, 2026, and the issuance and sale of the common stock and, if applicable, the pre-funded warrants are scheduled to settle on January 9, 2026, in each case subject to customary closing conditions. Arrowhead also granted the underwriters of the note offering a 30-day option to purchase up to an additional $75,000,000 principal amount of notes solely to cover over-allotments and granted the underwriters of the common stock and pre-funded warrant offering a 30-day option to purchase up to an additional 465,116 shares of common stock. The completion of the note offering will not be contingent on the completion of the common stock and pre-funded warrant offering, and the completion of the common stock and pre-funded warrant offering will not be contingent on the completion of the note offering.","length":1577,"tagName":"p"},{"type":"text","co...